Evidence map›Paper›PMID 41623379›Full record

ReviewPeerJ2026

Implications of LINC01094 for human malignancies.

Yan Wang, Yang Yang, Quanying Zhang, Ying Zeng, Yilin Cai, Haiqing Luo, Xiangyong Li

Abstract readReview
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan Wang *Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang, Guangdong, China.
Yang Yang *Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang, Guangdong, China.
Quanying ZhangInstitute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang, Guangdong, China.
Ying ZengCancer Hospital of The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Yilin CaiCancer Hospital of The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Haiqing LuoCancer Hospital of The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Xiangyong LiInstitute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) constitute a large class of ribonucleic acids, participating in multiple biological events within tumor cells, especially the regulation of transcription. A growing body of literature has revealed that abnormalities of lncRNA expression could result in carcinogenesis and oncogenesis by exerting inhibition or oncogenic effects. LINC01094 is a recently identified lncRNA found to be dys-regulated in an assortment of cancer tissues and control multiple biological processes via competing endogenous RNA (ceRNA) mechanisms. Specifically, LINC01094 functions as a ceRNA to modulate tumor cell growth, invasion, and migration by regulating critical signaling pathways including PI3K/AKT, PTEN/AKT, and Wnt/β-catenin, while also exerting oncogenic effects through transcriptional regulatory networks. Numerous recently published reports have shown that LINC01094 exerts critical functions during the regulation of malignant cell growth, migrating ability, and invasiveness, thereby controlling cancer cell growth and metastasis. In this review, multiple cancer biology functions of LINC01094 documented in published literature are summarized, aiming to inspire innovations in the management of human malignancies under laboratory and clinical settings.

Indexed as

Gene Expression Regulation, NeoplasticNeoplasmsRNA, Long NoncodingCell MovementCell ProliferationHumansNeoplasm InvasivenessRNA, Competitive EndogenousSignal TransductionRNA, Competitive EndogenousRNA, Long NoncodingCancersClinical characteristicsGrowth and metastasisLINC01094Molecular mechanisms

Identifiers

PMID41623379
PMCPMC12857556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.